At-Home Clinical Trials Are the Future

StatNews.com

Author Dr. Ben Green doesn’t just believe patients can be trusted to follow protocol from home, he believes that with the right technology and advice, clinical trials can happen at home, too.

Instead of requiring participants to travel for every appointment, we should be preparing participants and clinicians with the technology to make hybrid and decentralized trials work.

This article touches on how AliveCor’s KardiaMobile 6L ECG is a positive example of remote technology enabling more patient-centric, decentralized trials.

Key Takeaways

  • Studies have found improved enrollment and retention among hybrid and decentralized clinical trials
  • Many of the standard processes that take place on site can now be replaced by technology
  • ECGs are often recommended in clinical trials for drug and disease monitoring, including cardiac, oncologic, and psychiatric medications
  • Data collected via novel technologies must not only be high-quality and trusted but also delivered in familiar formats to trial researchers and clinicians
  • AliveCor technology meets quality and trust standards

Read Full Article

In The News

12 Ways to Improve Adherence

PM360online.com | With treatment plans that require frequent ECG testing, patients with breast cancer are faced with even more challenges. Leveraging KardiaMobile® 6L, an IQVIA program alleviated the pains associated with traditional 12-lead systems.

At-Home Clinical Trials Are the Future

StatNews.com | Hybrid and decentralized clinical trials are rapidly advancing. To ensure DCT success, mobile digital health technologies, like portable ECGs, are proving more necessary than ever.

Remote Monitoring Boosts Decentralized Trials

PharmExec.com | Decentralized trials are known to have positive effects, but sponsors have concerns about how to monitor patients well. Remote patient monitoring (RPM) solutions, like those from AliveCor, are changing this paradigm. The benefits that decentralized trials offer patients and sponsors are evident. Yet, decentralized trials are still lacking.